Autoimmune Biologics Deal Benchmarks

Median Upfront

$575M

Range: $304M - $835M

Total Deal Value

$3.0B

Range: $1.9B - $4.2B

Royalty Rate

14% - 23.4%

Tiered up to 27.4%

Dev Milestones

$490M

Range: $315M - $668M

Model Your Deal

Market Analysis

Autoimmune biologics remain one of the most actively licensed categories in biopharma, driven by large patient populations and proven commercial models. Phase 2 autoimmune biologic deals achieve a median total deal value of $3.0B, with upfront payments from $304M to $835M. The chronic treatment paradigm and multi-indication expansion potential create highly valuable licensing opportunities.

Milestone structures for autoimmune biologics balance development ($490M), regulatory ($858M), and commercial milestones ($1.1B). The 19/81 upfront/milestone structure reflects the de-risked Phase 2 stage and the established regulatory pathway for autoimmune indications.

Royalty rates range from 14% to 23.4% base, with escalation to 27.4% on blockbuster sales. Differentiation versus anti-TNF biologics, novel mechanisms (anti-TL1A, anti-IL-23, BCMA-targeting), and subcutaneous formulations drive premium royalty tiers. Multi-indication potential across RA, lupus, and IBD significantly enhances total deal economics.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average deal value for autoimmune biologic licensing?

Phase 2 autoimmune biologic deals average $3.0B total deal value with $575M upfront. Multi-indication potential across autoimmune conditions is the single biggest driver of premium valuations.

How does multi-indication potential affect autoimmune deal terms?

Biologics with validated mechanisms across multiple autoimmune indications (e.g., RA + lupus + IBD) command 25-50% higher total deal values versus single-indication assets. Licensors typically negotiate indication-specific milestone payments and may retain co-commercialization rights in select indications.

What autoimmune targets are commanding the highest deal premiums in 2026?

Novel targets with demonstrated efficacy beyond existing anti-TNF and anti-IL-17 therapies command the highest premiums. Anti-TL1A antibodies for IBD, BCMA-targeting biologics for lupus, and dual-cytokine inhibitors represent the current premium tier, with total deal values 30-60% above established mechanism classes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Autoimmune Biologics Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Monoclonal Antibody Deals

Immunology Deal Overview

Bispecific Antibody Deals

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?